Forte Biosciences Total Long Term Liabilities 2016-2025 | FBRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Forte Biosciences total long term liabilities from 2016 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Forte Biosciences Total Long Term Liabilities 2016-2025 | FBRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Forte Biosciences total long term liabilities from 2016 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$226.4B
Amgen (AMGN)	$166.3B
Gilead Sciences (GILD)	$141.3B
Vertex Pharmaceuticals (VRTX)	$122.5B
Bristol Myers Squibb (BMY)	$99.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$61.8B
Alnylam Pharmaceuticals (ALNY)	$42.5B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.2B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.2B
Illumina (ILMN)	$16.6B
Genmab (GNMSF)	$14.9B
Genmab (GMAB)	$14.7B
Incyte (INCY)	$13.7B
Moderna (MRNA)	$13.4B
Exelixis (EXEL)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.7B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B